Carthera Enrolls 100 Patients in Landmark SONOBIRD Trial Using Ultrasound to Breach Blood-Brain Barrier in Glioblastoma
• Carthera has reached a significant milestone in its SONOBIRD pivotal trial, enrolling 100 patients with recurrent glioblastoma across 40 sites in Europe and the US.
• The groundbreaking study evaluates SonoCloud, an implantable ultrasound device that temporarily opens the blood-brain barrier to enhance carboplatin delivery, compared to standard therapies.
• With FDA Breakthrough Device and Orphan Drug designations, the trial aims to enroll 560 patients by 2026, potentially transforming treatment options for this aggressive brain cancer.
© Copyright 2025. All Rights Reserved by MedPath